Cargando…

Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study

BACKGROUND: The goal of this research was to compare the demographics, clinical characteristics and treatment patterns for newly diagnosed multiple sclerosis (MS) patients in a commercial managed care population who received disease-modifying drug (DMD) therapy versus those not receiving DMD therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margolis, Jay M, Fowler, Robert, Johnson, Barbara H, Kassed, Cheryl A, Kahler, Kristijan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204236/ https://www.ncbi.nlm.nih.gov/pubmed/21974973 http://dx.doi.org/10.1186/1471-2377-11-122

Ejemplares similares

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Bowen, James, et al.
Publicado: (2020)

Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
por: Goodin, Douglas S., et al.
Publicado: (2014)

Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population
por: Dai, Dingwei, et al.
Publicado: (2022)

Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019
por: Zhu, Wen, et al.
Publicado: (2022)

Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data
por: Carroll, Cathryn A, et al.
Publicado: (2014)

Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Imaging the Addicted Human Brain
por: Fowler, Joanna S., et al.
Publicado: (2007)

Gender Differences in Self-Reported Symptom Awareness and Perceived Ability to Manage Therapy with Disease-Modifying Medication Among Commercially Insured Multiple Sclerosis Patients
por: Vlahiotis, Anna, et al.
Publicado: (2010)

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
por: Araujo, Lita, et al.
Publicado: (2023)

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Freeman, Leorah, et al.
Publicado: (2021)

Trends and patterns of initial percutaneous nephrolithotomy and subsequent procedures among commercially-insured US adults with urinary system stone disease: a 10-year population-based study
por: Johnston, Stephen S., et al.
Publicado: (2022)

Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States
por: Joshi, Kruti, et al.
Publicado: (2016)

Use of select medications prior to duloxetine initiation among commercially-insured patients
por: Bernauer, Mark, et al.
Publicado: (2012)

Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
por: Kale, Hrishikesh P., et al.
Publicado: (2021)

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis
por: Yawn, Barbara P, et al.
Publicado: (2013)

Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis
por: Meadows, Eric S, et al.
Publicado: (2012)

Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women
por: Balasubramanian, Akhila, et al.
Publicado: (2013)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

588. Retrospective Analysis of Clinical Characteristics and Treatment Patterns Among HIV Patients with Commercial and Medicare Advantage Health Insurance in the United States
por: Priest, Julie, et al.
Publicado: (2018)

SUN-597 Healthcare Utilization Patterns Among Commercially Insured Patients with Prader-Willi Syndrome: A Retrospective Analysis of Administrative Claims
por: Butler, Merlin G, et al.
Publicado: (2020)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Does the Development of the Insurance Industry Promote the Purchase of Rural Commercial Health Insurance?
por: Li, Cong, et al.
Publicado: (2021)

Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia
por: Zhao, Yang, et al.
Publicado: (2012)

Pricing in commercial dental insurance and provider markets
por: Nasseh, Kamyar, et al.
Publicado: (2020)

Pathways to reimagining commercial health insurance in India
por: Ashraf, Hasna, et al.
Publicado: (2022)

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States
por: Bozio, Catherine H., et al.
Publicado: (2020)

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
por: Boster, Aaron, et al.
Publicado: (2017)

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population
por: Kern, David M., et al.
Publicado: (2018)

Patterns of Use of a Price Transparency Tool for Childbirth Among Pregnant Individuals With Commercial Insurance
por: Gourevitch, Rebecca A., et al.
Publicado: (2021)

Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis
por: Placzek, Hilary, et al.
Publicado: (2015)

Temporal trend in the use of hysteroscopic vs laparoscopic sterilization and the characteristics of commercially insured and Medicaid-insured females in the US who have had the procedures
por: Carney, Patricia I, et al.
Publicado: (2016)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
por: Bonafede, Machaon M, et al.
Publicado: (2013)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance–A retrospective cohort study
por: Ramsey, Scott D., et al.
Publicado: (2022)

Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
por: Benson, Carmela, et al.
Publicado: (2020)

Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness
por: Järvinen, Elina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_24ir7fg9udhsqqlcilfgffnete